Acceleron shares have 30%-35% upside on ‘clean win,’ says JPMorgan

In a research note partially titled “Gooooal! A Clean Win for MEDALIST Phase 3,” JPMorgan analyst Eric Joseph raised his price target for Acceleron Pharma to $54 from $52. While details on specific endpoints were light, the top-line announcement notes highly significant outcomes on both primary and key secondary endpoint, Joseph writes. The analyst views the outcome as a “clean win” that and “materially de-risks” the path forward to approval for luspatercept. He sees 30%-35% upside to current levels for Acceleron shares on higher probability of success assumptions across Street models on myelodysplastic syndromes alone. Joseph keeps an Overweight rating on Acceleron. The stock in premarket trading is up 26.5% to $43.00

https://bit.ly/2IzTI4w